Cargando…

Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials

OBJECTIVE: To test the utility of longitudinal changes in plasma phosphorylated tau 181 (p-tau181) and neurofilament light chain (NfL) as surrogate markers for clinical trials targeting cognitively unimpaired (CU) populations. METHODS: We estimated the sample size needed to test a 25% drug effect wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferreira, Pamela C.L., Ferrari-Souza, João Pedro, Tissot, Cécile, Bellaver, Bruna, Leffa, Douglas T., Lussier, Firoza, Povala, Guilherme, Therriault, Joseph, Benedet, Andréa L., Ashton, Nicholas J., Cohen, Ann D., Lopez, Oscar L., Tudorascu, Dana L., Klunk, William E., Soucy, Jean-Paul, Gauthier, Serge, Villemagne, Victor, Zetterberg, Henrik, Blennow, Kaj, Rosa-Neto, Pedro, Zimmer, Eduardo R., Karikari, Thomas K., Pascoal, Tharick A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Clinical/Scientific Note
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351303/ https://www.ncbi.nlm.nih.gov/pubmed/36878697 http://dx.doi.org/10.1212/WNL.0000000000207115

Ejemplares similares

Astrocyte reactivity influences the association of amyloid-β and tau biomarkers in preclinical Alzheimer’s disease
por: Pascoal, Tharick, et al.
Publicado: (2023)

APOEε4 associates with microglial activation independently of Aβ plaques and tau tangles
por: Ferrari-Souza, João Pedro, et al.
Publicado: (2023)

Association of plasma P-tau181 with memory decline in non-demented adults
por: Therriault, Joseph, et al.
Publicado: (2021)

Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease
por: Bellaver, Bruna, et al.
Publicado: (2023)

Neuropsychiatric Symptoms and Microglial Activation in Patients with Alzheimer Disease
por: Schaffer Aguzzoli, Cristiano, et al.
Publicado: (2023)

Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease
por: Ferrari-Souza, João Pedro, et al.
Publicado: (2022)

Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals
por: Benedet, Andréa L., et al.
Publicado: (2019)

Biomarker modeling of Alzheimer’s disease using PET-based Braak staging
por: Therriault, Joseph, et al.
Publicado: (2022)

Amyloid‐dependent and amyloid‐independent effects of Tau in individuals without dementia
por: Therriault, Joseph, et al.
Publicado: (2021)

Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals
por: Lussier, Firoza Z, et al.
Publicado: (2021)

Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment
por: Pascoal, Tharick A., et al.
Publicado: (2020)

The Association of Age-Related and Off-Target Retention with Longitudinal Quantification of [(18)F]MK6240 Tau PET in Target Regions
por: Tissot, Cécile, et al.
Publicado: (2023)

Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer’s disease
por: Kang, Min Su, et al.
Publicado: (2020)

CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals
por: Simrén, Joel, et al.
Publicado: (2022)

Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography
por: Therriault, Joseph, et al.
Publicado: (2022)

Comparing tau status determined via plasma pTau181, pTau231 and [(18)F]MK6240 tau-PET
por: Tissot, Cécile, et al.
Publicado: (2022)

Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease
por: Tissot, Cécile, et al.
Publicado: (2021)

Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer's disease
por: Tissot, Cécile, et al.
Publicado: (2021)

Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE ε4, and Cognitive Impairment
por: Therriault, Joseph, et al.
Publicado: (2021)

APOEε4 potentiates the relationship between amyloid-β and tau pathologies
por: Therriault, Joseph, et al.
Publicado: (2020)

14-3-3 [Formula: see text] -reported early synaptic injury in Alzheimer’s disease is independently mediated by sTREM2
por: Woo, Marcel S., et al.
Publicado: (2023)

Interactive rather than independent effect of APOE and sex potentiates tau deposition in women
por: Wang, Yi-Ting T, et al.
Publicado: (2021)

A three‐range approach enhances the prognostic utility of CSF biomarkers in Alzheimer's disease
por: Brum, Wagner S., et al.
Publicado: (2022)

Topographic Distribution of Amyloid-β, Tau, and Atrophy in Patients With Behavioral/Dysexecutive Alzheimer Disease
por: Therriault, Joseph, et al.
Publicado: (2021)

Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies
por: Montoliu-Gaya, Laia, et al.
Publicado: (2023)

Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease
por: Ashton, Nicholas J., et al.
Publicado: (2022)

Discriminative accuracy of the A/T/N scheme to identify cognitive impairment due to Alzheimer's disease
por: Pascoal, Tharick A., et al.
Publicado: (2023)

Mitochondrial complex I abnormalities is associated with tau and clinical symptoms in mild Alzheimer’s disease
por: Terada, Tatsuhiro, et al.
Publicado: (2021)

Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Bayesian workflow for the investigation of hierarchical classification models from tau-PET and structural MRI data across the Alzheimer’s disease spectrum
por: Belasso, Clyde J., et al.
Publicado: (2023)

Blood neurofilament light in remote settings: Alternative protocols to support sample collection in challenging pre‐analytical conditions
por: Simrén, Joel, et al.
Publicado: (2021)

Mild behavioral impairment is associated with β‐amyloid but not tau or neurodegeneration in cognitively intact elderly individuals
por: Lussier, Firoza Z., et al.
Publicado: (2020)

Soluble amyloid-beta isoforms predict downstream Alzheimer’s disease pathology
por: Povala, Guilherme, et al.
Publicado: (2021)

Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer’s disease
por: Nilsson, Johanna, et al.
Publicado: (2022)

Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum
por: Gobom, Johan, et al.
Publicado: (2022)

Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease
por: Moscoso, Alexis, et al.
Publicado: (2021)

The accuracy and robustness of plasma biomarker models for amyloid PET positivity
por: Benedet, Andréa L., et al.
Publicado: (2022)

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

A multicentre validation study of the diagnostic value of plasma neurofilament light
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [(18)F]THK5351 uptake in progressive supranuclear palsy
por: Ng, Kok Pin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fuqsv3qqobu0uhdj5244hom6br